In this cohort of phase 2 dose-expansion trial, camrelizumab plus a low dose of apatinib as first-line therapy led to an encouraging ORR of 40% and median PFS of 9.6 months together with long-term survival in patients with high-TMB NSCLC irrespective of tumor PD-L1 expression. The gene discussed is CD274; the disease is neoplasm.